Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly (≥ 65 years) CLL patients: Results of the randomized CLL 2007 SA trial from the French FILO Group (NCT00645606).

Caroline Dartigeas,Eric Van Den Neste,Hervé Maisonneuve,Christian Berthou,Marie-Sarah Dilhuydy,Sophie de Guibert,Stéphane Leprêtre,Philippe Rodon,Thérèse Aurran,Jean Pierre Vilque,Beatrice Mahe,Marie C. Béné,Florence Nguyen-Khac,Remi Letestu,Alain Delmer,Pierre Feugier,Vincent Levy,Julie Léger,Philippe Colombat,Véronique Leblond

Rituximab maintenance after induction with abbreviated FCR in previously untreated elderly (≥ 65 years) CLL patients: Results of the randomized CLL 2007 SA trial from the French FILO Group (NCT00645606).

2016

7505Background: A promising concept to improve outcome in CLL is maintenance with immunotherapy after induction with FCR to improve quality and duration of response. Methods: Treatment-naive, ≥ 65 ...

Keywords:

Rituximab
Physical therapy
Medicine
Immunotherapy
Oncology
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations